Identifying causes of harmful reactions to medications
Official title: An integrative approach to identify biomarkers and investigate mechanisms of adverse drug reactions
Funded at Children's Mercy Hosp (Kansas City, Mo) · NIH-11011140 · Data updated 2026-11-12
This study is looking at how some people might have serious reactions to the antibiotic trimethoprim-sulfamethoxazole (TMP-SMX) and aims to find out if certain genes can help predict who might be at risk, so we can make medications safer for everyone.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Children's Mercy Hosp (Kansas City, Mo) NIH-funded |
| Lab location | 1 site (Kansas City, United States) |
| Project start | May 5, 2025 |
| Project end | February 28, 2030 |
| Funding year | 2025 |
| Award (this year) | $433,669 |
| NIH project number | 1R35GM156410-01 |
| Project ID | NIH-11011140 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include individuals who have experienced adverse reactions to medications, particularly those taking TMP-SMX.
✕Less likely to help
Patients who have not experienced any adverse drug reactions or who are not taking medications that could cause such reactions may not benefit from this research.
What this research studies
This research investigates the unpredictable and potentially life-threatening adverse drug reactions (IADRs) that can occur with certain medications, particularly focusing on the antibiotic trimethoprim-sulfamethoxazole (TMP-SMX). By examining genetic factors and how drug metabolites interact with the immune system, the study aims to identify biomarkers that can predict who may be at risk for these reactions. Patients may be involved in providing genetic samples and health information to help researchers understand the mechanisms behind these adverse reactions. The goal is to create a comprehensive platform that can improve drug safety and patient outcomes.
Why it matters
Potential benefit: If successful, this research could lead to better identification of patients at risk for severe drug reactions, ultimately improving medication safety.
How similar studies have gone: Previous research has shown promise in identifying genetic markers associated with adverse drug reactions, suggesting that this integrative approach could yield valuable insights.
Where this research is happening
-
Children's Mercy Hosp (Kansas City, Mo)
Kansas City, United States Active
Researchers
- Principal investigator: Goldman, Jennifer Lynn — Children's Mercy Hosp (Kansas City, Mo)
- Study coordinator: Goldman, Jennifer Lynn
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.